Palvella Therapeutics to Present at Upcoming Healthcare Investor Conferences

Core Insights - Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for serious, rare genetic skin diseases without FDA-approved treatments [1][3] - The company will present at two upcoming healthcare investor conferences, highlighting its commitment to engaging with investors [1][2] Company Overview - Founded by veterans in rare disease drug development, Palvella is dedicated to creating novel therapies for patients with serious, rare genetic skin diseases [3] - The company is developing a pipeline of product candidates using its patented QTORIN™ platform, with a focus on lifelong genetic skin diseases [3] - Palvella's lead product candidate, QTORIN™ 3.9% rapamycin anhydrous gel, is currently in Phase 3 and Phase 2 clinical trials for specific conditions [3] Upcoming Events - Wes Kaupinen, the CEO, will present at the Cantor Global Healthcare Conference on September 4, 2025, and at the H.C. Wainwright 27th Annual Global Investment Conference on September 8, 2025 [2] - Live webcasts of the presentations will be available on Palvella's website, with archived replays accessible for approximately 90 days [2]